ABSTRACT
Avaliou-se o efeito antinociceptivo e condroprotetor de sulfato de glicosamina e condroitina em um modelo de osteoartrite por transeccção do ligamento cruzado anterior em ratos. Os animais receberam sulfato de glicosamina ou sua combinação com sulfato de condroitina por 100 dias. A dor articular foi avaliada pelo tempo de suspensão da pata operada durante a deambulação e o dano articular por análise histopatológica dos côndilos femorais e quantificação de glicosaminoglicanos na cartilagem. A combinação mostrou-se eficaz tanto na redução da dor como do dano articular, sugerindo melhora funcional e estrutural com o uso da associação de sulfato glicosamina e condroitina na osteoartrite.
Antinociceptive and chondroprotective effects of glucosamine and chondroitin sulphate were evaluated in the osteoarthritis model of anterior cruciate ligament transection in rats. Animals received glucosamine sulphate or its combination with chondroitin sulphate for 100 days. Joint pain was evaluated by paw elevation time, and articular damage by histopathological analysis of femoral condyles and cartilage quantification of glycosaminoglycans. The combination of the compounds was efficient in reducing both joint pain and joint damage, suggesting functional and structural benefits of the combination of glucosamine and chondroitin sulphate in osteoarthritis.
Subject(s)
Animals , Male , Rats , Arthralgia/physiopathology , Osteoarthritis/chemically induced , Chondroitin Sulfates/adverse effects , Glycosaminoglycans/adverse effects , Glucosamine/adverse effects , Anterior Cruciate Ligament/physiopathology , Models, Animal , Pain Measurement , Rats, WistarABSTRACT
O trabalho objetivou a avaliaçäo do efeito do GAG sulfato de condroitina (SC) sobre a cristalizaçäo do oxalato de cálcio monohidratado (COM), em ratos wistar machos. Para a induçäo da cristalúria usou-se do Etilenoglicol a 1,2 porcento na água de beber, VO, (EG, n = 18), e para a avaliaçäo do efeito do GAG sobre a cristalúria foi usado, além do Etilenoglicol, conforme o grupo anterior, um preparado comercial de SC na dose diária de 10mg/rato administrata por via intraperitoneal (EG + GAG, n= 15). Também se avaliou dois grupos controles: o que recebeu apenas SC (GAG, n= 5) e o normal, constituído de animais que näo receberam nenhuma droga (NL, n= 11). Os resultados comprovam que SC modificou o processo de cristalizaçäo do oxalato de cálcio monohidratado in vivo, promovendo o desaparecimento da cristalúria e tornando a deposiçäo intrabular de cristais mais expressiva: EG + GAG vx EG: 1,55 vs 0,5 cristal/campo. Os autores discutem que o desaparecimento da cristalúria näo pode ser atribuído apenas a uma maior retençäo intrabular dos cristais formados mas sim a uma inibiçäo do crescimento propriamente dito dos núcleos cristalinos decorrentes da hiperoxalúria
Subject(s)
Animals , Rats , Calcium Oxalate/adverse effects , Chondroitin Sulfates , Ethylene Glycol/adverse effects , Glycosaminoglycans/adverse effects , Hyperoxaluria , Crystallization , Urine/virologyABSTRACT
We performed clinical trials to evaluate the therapeutic effects of Foltene in patients of the several types of hair fallings. Thirty patients with male pattern baldness, alopecia areata and seborrheic alopecia were included in this study. Foltene was applied every other day for 40 days, and followed by maintenance therapy of twice application a week. The duration of whole therapy was 6 months. We conclude that Foltene is an effective and agent for male pattern baldness, alopecia areata and seborrheic alopecia from the following results. Ten patients with male pattern baldness was treated with Foltene for 6 months. Foltene had therapeutic effects of 50% in hair regrowth, 70% in decreased hair falls, 30% in decreased dandruff, 50% in decreased seborrhea. Thirteen patients with alopecia areata was treated with Foltene for 6 months. Foltene had therapeutic effects of 61.6% in hair regrowth, 53.9% in decreased in hair falls, 53.9% in decreased dandruff, 77.0% in decreased seborrhea. Seven patients with seborrheic alopecia was treatment with Foltene for 6 months. Foltene had therapeutic effects of 85.8% in hair regrowth, 57.2% in decreased hair falls, 42.9% in decreased dandruff, 85.8% in decreased seborrhea. The degree of therapeutic success was related to the duration of therapy. The side effects were as followed: itching sensation developed in 2 patients (6.7%); tingling sensation in 3 patients (10.0%); burning sensation in 1 patient (3.3%); erythema in 3 patients (10.0%).